Abbott

Company Utilizing New Manufacturing Practices and Technologies

November 2, 2009 -- Abbott Park, Illinois (NYSE: ABT) — Abbott announced today that it is saving 1 billion gallons of water annually since launching a comprehensive, global effort in 2004 to preserve natural resources through reducing use of water in the production of its nutrition and other health care products.

In 2004, the company set out to achieve a reduction in water use compared to its 2004 baseline by the end of 2011, when normalized to sales.    » read more »

November 2, 2009 -- Abbott Park, Illinois (NYSE: ABT) — Abbott announced today that it has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves.

The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease.Evalve's minimally invasive catheter-based MitraClip® system is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation – a condition that prevents the heart's mitral valve from closing completely The MitraClip system is an investigational device in the United States and is currently in clinical trials.    » read more »

Protein Marker Test Aids in the Early Diagnosis of Kidney Injury and Reduces Wait Time from Days to Hours

October 06, 2009 -- Abbott Park, Illinois (NYSE: ABT) — Abbott announced today it has received CE Marking (Conformité Européene) for a new diagnostic test that detects an important protein in urine, neutrophil gelatinase-associated lipocalin (NGAL), an early marker or indicator for patients with, or at risk of, acute kidney injury (AKI).    » read more »

World Premiere of LEARN Exhibit Educates on Autoimmune Diseases with Tour Inside the Immune System

June 11, 2009 -- Copenhagen, Denmark — Today at the European League Against Rheumatism (EULAR) congress, LEARN, a unique travel exhibit that provides a walking tour of the immune system and its response to autoimmune diseases, makes its world debut.

Abbott (NYSE: ABT), the global health care company, several Danish patient associations and Hvidovre Hospital in Denmark have joined together in an effort to increase awareness of autoimmune diseases by creating the Living the Experience of Autoimmune ReactioNs (LEARN) exhibit. The LEARN international media event is scheduled for Thursday, June 11, 2009, in Copenhagen's Town Square from 8:15 - 9:30 a.m. (CEST).    » read more »

Used for the Treatment of Mixed Dyslipidemia

June 4, 2009 -- AstraZeneca and Abbott announced today that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL cholesterol (the “bad” cholesterol), high triglycerides and low HDL-cholesterol (the “good” cholesterol).    » read more »

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease

Abbott Park, Illinois, July 2, 2008 -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE™ V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS® paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.    » read more »

March 18, 2008 -- Jefferson City, Mo. — Missouri Attorney General Jay Nixon was joined by 17 other states and the District of Columbia today in filing a lawsuit against pharmaceutical companies Abbott Laboratories and Fournier. The lawsuit alleges that the companies conspired to violate antitrust laws in delaying the availability of a cheaper, generic version of the cholesterol drug TriCor. TriCor accounted for over one billion dollars in sales for Abbott one year ago.    » read more »

BALTIMORE, MD (March 18, 2008) - Maryland Attorney General Douglas F. Gansler today filed suit against Abbott Laboratories and French drug company Fournier Industrie et Sante alleging that the firms violated state and federal antitrust laws by delaying the availability of cheaper, generic versions of TriCor, a cholesterol drug which last year accounted for over one billion dollars of Abbott’s sales.    » read more »

Abbott and French drug company face allegations they blocked generic versions of a cholesterol drug

March 18, 2008 -- TALLAHASSEE, FL – Florida Attorney General Bill McCollum today announced that Florida and 18 states have filed an antitrust lawsuit against Abbott Laboratories and French drug company Fournier Industrie et Sante and Laboratories Fournier, S.A., charging the companies with blocking a cheaper, generic version of prescription drug TriCor.    » read more »

Abbott Park, Illinois, October 10, 2007 – Abbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine’s "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.    » read more »